Antibody-drug conjugates in the perioperative treatment of resectable non-small cell lung cancer: a narrative review of research advances and prospects
Background and Objective Lung cancer is the leading cause of cancer-related mortality worldwide. Even after perioperative chemotherapy combined with immunotherapy, pathological complete response (pCR) rates remain below 30%, and further improvement in long-term outcomes has stalled. Antibody-drug conjugates (ADCs), lev...